EVALUATION OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR FOR THE LABORATORY DIAGNOSIS OF RHEUMATOID ARTHRITIS

NAWFAL Y. AL-DABBAGH; ZHARA A. HASHIM

NAWFAL Y. AL-DABBAGH Department of Medical Analysis Technique, El-Kitab University College, Kirkuk, Iraq
ZHARA A. HASHIM Department of Pharmacology, College of Pharmacy, University of Mosul, Mosul, Iraq

Keywords: RF, RAanti-CCP2 antibody, DAS28, score, rheumatoid factor, rheumatoid arthritis

Abstract

https://doi.org/10.31386/dmj.uod.18.12.1.5

Background: 1-Assess the correlation between Anti-cyclic citralliuated peptide (anti-CCP2) antibodies concentration with some clinical and laboratory parameters of rheumatoid arthritis (RA): 2-Evaluate the differences in the clinical and serological parameters between antiCCP2+ve and anti-CCP2-ve patients and Rheumatoid factor (RF+ve and RF-ve) patients. 3-Assess the relationship between smoking history and the detection of anti-CCP2 and RF auto antibodies. Subject and Methods: This is a case-control study carried out on 55 patients with established RA attending the Rheumatology ward of Ibn-Sina Teaching Hospital in Nineveh Governorate during the period from 1st November 2010 to the 1st June 2011 and 35 apparently healthy individuals as a control. Anti-CCP2 antibodies were measured using enzyme linked immunosorbent assay (ELISA).The RF was tested by latex agglutination and ELISA. C-reactive protein (CRP) was measured by Latex agglutination test. Patients' demographic data, disease activity and duration and erythrocyte sedimentation rate (ESR) were also recorded Results: Anti-CCP2 antibodies were found significantly associated with RF, total swollen joints (TSJ) and total tender joints (TTJ) counts (p <0.05) while the correlation with ESR, CRP, disease activity score 28 (DAS28) and disease duration was not significant (p>0.05). In RA patients with smoking history and joints deformity, anti-CCP2antibodies was more often detected. The same results were obtained for RF seropositivity. It was also found that the differences between RF+ve and RF-ve groups were comparable to those between anti-CCP2+ve and anti-CCP-2ve groups except for ESR and CRP. Conclusions: The study suggests that the seropositivity of RF is inflammation driven, whereas, the appearance of anti-CCP antibodies might suggests pathophysiological properties and a possible contribution to on-going immune activation

Downloads

Download data is not yet available.

References

1. Herold M, Boeser V, Russe E, et al. Anti-CCP: History and its usefulness. Clin. Develop. Immunol. 2005; 12(2): 131-135.
2. Tobon GJ, Youinou P and Saraux A. The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. Autoimmun, 2010. Rev.; 9(5): 288-292.
3. Arnett FC, Edworthy SM, Bloch DA, et al.TheAmericanRheumatism Association 1987 revised criteria for the classification ofrheumatoid arthritis. Arthritis. Rheum. 1988; 31:315-324.
4. Ng KP, Austin P, Ameratunga R, et al. Role of anti cyclic citrullinated peptide 2 assay in longstanding rheumatoid arthritis. APLAR J., Rheumatol 2006,9:211-215.
5. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/EuropeanLeague Against Rheumatism collaborative initiative. Ann. Rheum. Disf 2010;69:1580-8518.
6. Westwood OM, Nelson PN and Hay FC. Rheumatoid factors: what's new?. Oxford J. Rheumatol 2006;45 (4): 379-385.
7. Goodson NJ, Fagherrra T and Symmons DM. Rheumatoid Factor, Smoking, and Disease Severity; Associations with Mortality in Rheumatoid Arthritis. J. Rheumatol 2008;35;945-949.
8. Jaskowski TD, Hill HR, Russo KL, et al. Relationship Between Rheumatoid Factor Isotypes and IgG Anti-Cyclic Citrullinated Peptide Antibodies. J. Rheumatol 2010;37:8.
9. Meyer O, Labarre C, Dougados M, et al. Anticitrullinatedprotein/peptide antibody assays in early rheumatoid arthritis for predictingfive year radiographic damage. Ann. Rheum. Dis 2003, 62: 120-126.
10. Visser H, Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. ArthritisRheum. 2002;46:357-365.
11. Prevoo ML, van't Hof MA, Kuper HH, et al. Modifieddiseaseactivity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48.
12. Saadeh C. The erythrocyte sedimentation rate: old and newclinical applications. South Med. JI, 1998;3:220-225.
13. Bettyr R Kirkwood. Essential of medical statistic. Black well Scientific publication. 1988 Chapter(7,8), pp:41-56.
14. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatol 2004;43:906-914.
15. Serdaroglu M, Cakirbay H, Deger O, et al. The association of anti-CCP antibodies .with disease activity in rheumatoid arthritis.RheumatolInt. 2008, 28:965-970.
16. Agyei-Frempong MT, Sakyi SA and Quansah RE. Comparison of Anti-CCP Peptide with Rheumatoid Factor and its Isotypes for Early Differential Diagnosis and Prognosis of Rheumatoid Arthritis. J. Med. Sci; 2010, 10(l):19-24.
17. Milovanoic M, Nilson E and Jaremo P. Relationship between platelets and inflammatory markers in rheumatoid arthritis. Clin. Chim. Actal; 2004, 343(l-2):237-240.
18. Pincus T and Sokka T. Prevalence of normal erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) on presentation of patients with rheumatoid arthritis (RA) at two rheumatology settings, one in the US and the other in Finland: Is a patient questionnaire better quantitative measure of clinical severity? Arthritis Rheum; 2005, 52(9): 127.
19. Van der Helm-Van MM AH, Verpoort KN, Breedveld FC, et al.Antibodies to citrullinated proteins and differences in clinical progression ofrheumatoid arthritis. Arthritis Res. Ther. 2005;7:R949-958.
20. Bos WH, Nielen MMJ, Dijkmans BAC, et al. Duration of pre- rheumatoid arthritis anti-cyclic citrullinated peptide positivityis
positively associated with age at seroconversion. Ann. Rheum. Disi 2008;67:1642.
21. Makinen H, Kautiainen H, Hannonen P, et al. Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis. J Rheumatoid 2007, 34(10): 1987-1991.
22. Li H, Song W, Li Y, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity; Clin. Rheumatol 2010; 29(4):413-417.
23. Schellekens GA, Visser H, de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cycliccitrullinated peptide. Arthritis Rheum. 2000;43:155-163.
24. Gupta R, Thabah MM, Aneja R, et al. Usefulness of anti –CCPantibodies in rheumatic diseases in Indian patients. I. J. Med. Sci. 2009, 63(Issue 3):92-100.
25. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Anti-bodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheumi 2003;48:2741-2749.
26. Inane N, Dalkilic E, Kamali S, et al. Anti-CCP antibodies inrheumatoid arthritis and psoriatic arthritis. Clin. Rheumatol 2007, 26:17-23.
27. Ronnelid J, Wick NIC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CCP) during a 5-year follow-up in early rheumatoid arthritis: anti-CCP status predicts worsedisease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749.
28. Domer T, Egerer K, Feist E, et al. Rheumatoid factor revisited. Curr. Opin. Rheumatol. 2004; 16:246-253.
29. Hill JA, Southwood S, Sette A, et al. The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB 1*0401 MHC class II molecule. J. Immunol. 2003; 171:538-541.
30. Alsalahy MM, Nasser HS, Hashem MM, et al. Effect of tobacco smoking on tissue protein citrullination and disease progression in patients with rheumatoid arthritis. Saudi Pharmaceutical J 2010;18 (Issue 2):75-80.